Allogennaya transplantatsiya kletok pupovinnoy krovi u bol'nykh s nekhodzhkinskimi limfomami


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Высокодозная химиотерапия с последующей аллогенной трансплантацией гемопоэтических стволовых клеток (ГСК) является наиболее эффективным методом лечения у взрослых онкогематологических больных с высоким риском, однако, только треть из них имеет родственных доноров. Одним из альтернативных источников аллогенных ГСК в настоящее время стали клетки пуповинной крови. Использование клеток пуповинной крови применимо для лечения взрослых больных с резистентными формами высокоагрессивных лимфом, которым уже была выполнена аутогенная трансплантация периферических стволовых кроветворных клеток, в случае отсутствия потенциального подходящего по HLA донора.

About the authors

A V Novitskiy

Email: anov@mail.ru

M S Fominykh

References

  1. Gluckman E., Broxmeyer H.A., Auerbach A.D. et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 1989; 321: 1174-8.
  2. Wagner J.E., Gluckman E. Umbilical Cord Blood Transplantation: The First 20 Years. Seminars in Hematology 2010; 47(1): 3-12.
  3. Mayani H. Biological differences between neonatal and adult human hematopoietic stem/progenitor cells. Stem Cells Dev. 2010; 19(3): 285-98.
  4. Noort W.A., Falkenburg I.H.F. Hematopoietic content of cord blood. In: Cord blood characteristics. Role in stem cell transplantation. S.B.A. Cohen, E. Gluckman, A. Madrigal, P. Rubinstein (eds). 2000: 13-37.
  5. Series I.M., Pichette J., Carrier C. et al. Quantitative analysis of T- and B-cell subsets in healthy and sick premature infants. Early Hum. Dev. 1994; 26: 143-54.
  6. Bertotto A., Arcangeli C.D.F., Gerli R. et al. Phenotypic heterogeneity within the circulating human neonatal T4-positive T-cell subset. Biol. Neonate 1986; 50: 318-22.
  7. Barker J., Krepski T.P., DeFor T.E. et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol. Blood Marrow Transplant. 2002; 8: 257-60.
  8. Laughin M.J. Umbilical cord blood for allogeneic transplantation in children and adults. Bone marrow Transplant. 2001; 27: 1-6.
  9. Энциклопедия клинической онкологии: Руководство для практикующих врачей. - М.: РЛС-2005; 2005: 1356.
  10. Majhail N.S., Brunstein C.G., Wagner J.E. Double umbilical cord blood transplantation. Current Opinion Immunol. 2006, 18: 571-5.
  11. Piacibello W., Sanavio F., Garetto L. et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89: 2644-53.
  12. Piacibello W., Sanavio F., Severino A. et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999; 93: 3736-49.
  13. Broxmeyer H.E., Kohli L., Kim C.H. et al. Stromal cell-derived factor 1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J. Leuk. Biol. 2003; 73: 630-8.
  14. Broxmeyer H.E., Cooper S., Kohli L. et al. Transgenic expression of stromal cell derived factor-1/CXCL12 enhances myeloid progenitor cell survival/anti-apoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J. Immunol. 2003; 170: 421-9.
  15. Lee Y., Gotoh A., Kwon H-J. et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/ CXCL12 in synergy with other cytokines. Blood 2002; 99: 4307-17.
  16. Guo Y., Hangoc G., Bian H. et al. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells 2005; 23: 1324-32.
  17. Broxmeyer H.E., Mejia J.A.H., Hangoc G. et al. SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev. 2007; 16: 589-96.
  18. Yahata T., Ando K., Sato T., et al. A highly sensitive strategy for SCID repopulating cell assay by direct injection of primitive human hematopoeitic cells into NOD/SCID mice bone marrow. Blood 2003; 101: 2905-13.
  19. Van Besien K., Sobocinski K.A., Rowlings P.A. et al. Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma. Blood 1998; 92: 1832-36.
  20. Van Besien K., Loberiza F.R. Jr., Bajorunaite R. et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102(10): 3521-9.
  21. Levine J.E., Harris R.E., Loberiza F.R. Jr. et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476-84.
  22. Yakoub-Agha I., Fawaz A., Folliot O. et al. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplant. 2002; 30: 229-34.
  23. Knouri I. F., Saliba R.M., Giralt S. A. et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-9.
  24. Rocha V., Cornish J., Sievers E. L. et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-71.
  25. Blay J., Gomez F., Sebban C. et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998; 92: 3562-8.
  26. Freedman A.S., Neuberg D., Mauch P.et al. Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. Blood 1999; 94: 3325015033.
  27. Hunault-Berger M., Ifrah N., Solal-Celigny P. et al. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100(4): 1114-52.
  28. Laddeto M., Corradini P., Vallet S. et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100(5): 1559-65.
  29. Koichiro Y., Shigesaburo M., Daisuke K. et al. Reduced-Intensity Unrelated Cord Blood Transplantation for Patients with Advanced Malignant Lymphoma. Biol. Blood Marrow Transpl. 2005; 11: 314-8.
  30. Penn I. Malignancy. Surg. Clin. N. Amer. 1994; 75: 1247-57.
  31. Pettengell R., Ragford J., Margestern G. et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J. Clinic. Oncol. 1996; 14(2): 586-92.
  32. Morrison W.H., Hoppe R.T., Weiss L.M. et al. Small lymphocytic lymphoma. J. Clinic. Oncol. 1989; 7: 598-606.
  33. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2010.
  34. Brunstein C.G., Cantero S., Cao Q. et al. Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation. Biol. Blood Marrow Transplant. 2009; 15: 214-22.
  35. Rodrigues C.A., Sanz G., Brunstein C.G. et al. Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 2009; 27(2): 256-63.
  36. Chopra R., Goldstone A.H., Pearce R. et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J. Clin. Oncol. 1992; 10: 1690-5.
  37. Verdonck L.F., Dekker A.W., Lokhorst H.M. et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-5.
  38. Khouri I.F., Keating M., Korbling M. et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 1998; 16: 2817-24.
  39. Goldstone A.H., Kottaridis P.D. The allogeneic effect in non-Hodgkin's lymphoma. Leuk. Lymph. 2003; 44(suppl 3): 91-7.
  40. Branson K., Chopra R., Kottaridis P.D. et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J. Clin. Oncol. 2002; 20: 4022-31.
  41. Tanimoto T.E., Kusumi E., Hamaki T. et al. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transpl. 2003; 32: 131-7.
  42. Khouri I.F., Saliba R.M., Giralt S.A. et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-9.
  43. Hofmeister C., Zhang J., Knight K.L. et al. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant. 2007; 39: 11-23.
  44. Sato Т., Laver J.H., Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 1999; 94: 2548-54

Copyright (c) 2011 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies